selumetinib
Showing 101 - 109 of 109
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma Trial in United States (Akt
Completed
- Pancreatic Acinar Cell Carcinoma
- +3 more
- Akt Inhibitor MK2206
- +3 more
-
Tucson, Arizona
- +533 more
Feb 10, 2016
Solid Tumours Trial in Overland Park (selumetinib (oral))
Completed
- Solid Tumours
- selumetinib (oral)
-
Overland Park, KansasResearch Site
Aug 12, 2014
Healthy Volunteers Pharmacokinetic Study Trial in London (Selumetinib)
Completed
- Healthy Volunteers Pharmacokinetic Study
- Selumetinib
-
London, United KingdomResearch Site
May 30, 2014
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma Trial in United States (Akt inhibitor MK2206, selumetinib,
Terminated
- Recurrent Melanoma
- +4 more
- Akt inhibitor MK2206
- +2 more
-
Atlanta, Georgia
- +3 more
May 16, 2014
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Completed
- Adult Primary Hepatocellular Carcinoma
- +3 more
- selumetinib
- pharmacological study
-
Tampa, Florida
- +5 more
May 12, 2014
Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma Trial in Tampa (temsirolimus, selumetinib, laboratory biomarker
Terminated
- Mucosal Melanoma
- +2 more
- temsirolimus
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Apr 29, 2014
Colorectal Tumors Trial run by the NCI (MK-2206 + AZD6244)
Completed
- Colorectal Neoplasms
- MK-2206 + AZD6244
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 29, 2015